Effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile in patients with non-alcoholic fatty liver disease: a double-blind randomised controlled clinical trial
- 21 April 2020
- journal article
- research article
- Published by Cambridge University Press (CUP) in British Journal of Nutrition
- Vol. 124 (4), 450-456
- https://doi.org/10.1017/s0007114520001403
Abstract
Non-alcoholic fatty liver disease (NAFLD) includes a range of disorders from simple steatosis to non-alcoholic steatohepatitis. There is no proven drug treatment for NAFLD, and diet modification is considered part of the main line of treatment for this disease. The aim of this study was to investigate the efficacy of garlic supplementation in NAFLD patients. The effect of garlic powder supplementation on hepatic steatosis, liver enzymes and lipid profile was investigated in NAFLD patients. Ninety NAFLD patients were randomly assigned to take either a garlic powder supplement or a placebo for 12 weeks. The treatment group received four tablets of garlic daily (each tablet contained 400 mg garlic powder). The control group received four tablets of placebo (each placebo contained 400 mg starch). At the end of the study, hepatic steatosis was significantly reduced in the treatment group compared with the control group (P = 0·001). In addition, a significant decrease was seen in the serum concentration of alanine transaminase (P < 0·001), aspartate transaminase (P = 0·002), γ-glutamyltransferase (P = 0·003) as well as total cholesterol (P = 0·009), TAG (P < 0·001), HDL-cholesterol (P < 0·001) and LDL-cholesterol (P = 0·01) in the treatment group compared with the control group. No significant difference was seen between the two groups in serum concentration of alkaline phosphatase. Overall, garlic powder supplementation improved hepatic features and lipid profile among NAFLD patients.Keywords
This publication has 27 references indexed in Scilit:
- Reduction of blood lipid parameters by a 12-wk supplementation of aged black garlic: A randomized controlled trialNutrition, 2014
- Diagnosis and management of non‐alcoholic fatty liver disease and related metabolic disorders: Consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology (非酒精性脂肪性肝病与相关代谢紊乱诊疗共识——中华医学会内分泌学分会肝病与代谢学组)Journal of Diabetes, 2013
- A Review of the Cardiovascular Benefits and Antioxidant Properties of AllicinPhytotherapy Research, 2012
- The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological AssociationHepatology, 2012
- Garlic-derived S-allylmercaptocysteine is a hepato-protective agent in non-alcoholic fatty liver disease in vivo animal modelEuropean Journal of Nutrition, 2012
- Garlic improves insulin sensitivity and associated metabolic syndromes in fructose fed ratsNutrition & Metabolism, 2011
- Effect of garlic on liver phosphatidate phosphohydrolase and plasma lipid levels in hyperlipidemic ratsFood and Chemical Toxicology, 2011
- Biological properties of garlic and garlic‐derived organosulfur compoundsEnvironmental and Molecular Mutagenesis, 2009
- Steatohepatitis: A tale of two “hits”?Gastroenterology, 1998
- Echogenicity: analysis, significance, and maskingAmerican Journal of Roentgenology, 1981